Voyager Awarded Cancer Research Mission Management Contract
Business Wire•06/10/2026•09:00 ET
0
Key Highlights
- ➤Voyager signed ISS mission-management contract with CASIS for Symphony’s cancer implant experiment
- ➤SymphNode tests whether trained immune cells can restore T-cell responses against tumors
- ➤Voyager will manage hardware adaptation, NASA safety reviews, launch integration, and on-orbit operations
- ➤Voyager will return research samples and data and provide post-flight reporting
Expert Statements
Scott Rodriguez, Vice President, Government Programs, Voyager Technologies
“Our mission management service exists to clear the obstacles between breakthrough research and low-Earth orbit”
Scott Rodriguez, Vice President, Government Programs, Voyager Technologies
“Microgravity provides a cancer research environment where tumor cells form complex, three-dimensional structures that are obscured in Earth cultures, and our role is to make sure nothing stands between companies like Symphony Biosciences and unlocking better ways to fight cancer and improve life on Earth.”
Mission tests an implant designed to train immune cells to attack tumors
Voyager Technologies (NYSE: VOYG) signed a contract with the Center for the Advancement of Science in Space to manage Symphony Biosciences’ biopolymer cancer implant experiment aboard the International Space Station (ISS). The contract underscores the continued demand for access to low-Earth orbit for biopharmaceutical research.
Get started
Create a free account to read the full story.